[go: up one dir, main page]

MX2017000142A - Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica. - Google Patents

Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.

Info

Publication number
MX2017000142A
MX2017000142A MX2017000142A MX2017000142A MX2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A MX 2017000142 A MX2017000142 A MX 2017000142A
Authority
MX
Mexico
Prior art keywords
stromal cells
mesenchymal stromal
treating sepsis
sepsis
treating
Prior art date
Application number
MX2017000142A
Other languages
English (en)
Other versions
MX381544B (es
Inventor
Dekker Robert
Lombardo Eleuterio
Dalemans Wilfried
Original Assignee
Tigenix S A U
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A U filed Critical Tigenix S A U
Publication of MX2017000142A publication Critical patent/MX2017000142A/es
Publication of MX381544B publication Critical patent/MX381544B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Genetics & Genomics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)

Abstract

La invencion se refiere al uso de celulas estromales mesenquimatosas (MSCs) para tratar la sepsis en un sujeto. La invencion proporciona composiciones, usos y metodos para el tratamiento de la sepsis.
MX2017000142A 2014-06-30 2015-06-30 Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto. MX381544B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14175095 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (2)

Publication Number Publication Date
MX2017000142A true MX2017000142A (es) 2017-07-28
MX381544B MX381544B (es) 2025-03-12

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000142A MX381544B (es) 2014-06-30 2015-06-30 Composición de células estromales mesenquimatosas para usare en el tratamiento de la sepsis en un sujeto.

Country Status (14)

Country Link
US (2) US20170151284A1 (es)
EP (1) EP3160481B1 (es)
JP (1) JP6722599B2 (es)
KR (1) KR102213527B1 (es)
CN (1) CN106573017B (es)
AU (1) AU2015283662B2 (es)
BR (1) BR112016030758B8 (es)
CA (1) CA2953884C (es)
IL (1) IL249814B (es)
MX (1) MX381544B (es)
NZ (1) NZ727950A (es)
RU (1) RU2715866C2 (es)
SG (1) SG11201610844PA (es)
WO (1) WO2016001846A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6714932B2 (ja) * 2015-12-01 2020-07-01 株式会社ＡｄｉｐｏＳｅｅｄｓ 脊椎動物の脂肪組織由来間葉系細胞株の製造方法
WO2017156235A1 (en) * 2016-03-09 2017-09-14 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
CA3054588A1 (en) 2017-02-28 2018-09-07 Universite De Lorraine Mesenchymal stem cells obtained from wharton's jelly for the treatment of sepsis
EP3700524A4 (en) 2017-10-26 2021-08-25 Emory University MCL-1 INHIBITORS, COMPOSITIONS AND USES IN THE MANAGEMENT OF CANCER
AU2019283518A1 (en) * 2018-06-05 2021-01-14 Medipost Co., Ltd. Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
CA3116196A1 (en) * 2018-10-29 2020-05-07 Ottawa Hospital Research Institute Genetically-engineered mesenchymal stem cells overexpressing aoah and uses thereof
EP4098267A4 (en) * 2020-01-30 2024-03-06 JCR Pharmaceuticals Co., Ltd. MEDICINAL COMPOSITION COMPRISING CELLS DERIVED FROM DENTAL PULP
WO2022241090A1 (en) * 2021-05-13 2022-11-17 Primegen Us, Inc. Methods and compositions for treating liver disease
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE163921T1 (de) 1992-12-02 1998-03-15 Shell Int Research Azoxycyanbenzol-derivate
US5578475A (en) 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
AU723163B2 (en) 1995-06-07 2000-08-17 Tekmira Pharmaceuticals Corporation Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20050239897A1 (en) * 2004-03-22 2005-10-27 Pittenger Mark F Mesenchymal stem cells and uses therefor
CN107723274B (zh) 2005-09-23 2021-05-07 塞勒里克斯有限公司 具有免疫调节活性的细胞群及其分离方法和用途
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
CN103648509B (zh) * 2011-03-11 2019-02-22 儿童医学中心公司 与间充质干细胞外来体相关的方法和组合物
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
BR112016030758B8 (pt) 2022-10-25
US20200376038A1 (en) 2020-12-03
MX381544B (es) 2025-03-12
CN106573017B (zh) 2021-06-11
CA2953884A1 (en) 2016-01-07
IL249814B (en) 2020-02-27
RU2016151738A (ru) 2018-07-30
NZ727950A (en) 2022-07-01
JP2017520583A (ja) 2017-07-27
JP6722599B2 (ja) 2020-07-15
US20170151284A1 (en) 2017-06-01
EP3160481A1 (en) 2017-05-03
AU2015283662A1 (en) 2017-01-19
EP3160481B1 (en) 2020-09-09
CN106573017A (zh) 2017-04-19
CA2953884C (en) 2022-12-06
BR112016030758A2 (es) 2017-08-22
KR20170021343A (ko) 2017-02-27
SG11201610844PA (en) 2017-01-27
RU2715866C2 (ru) 2020-03-03
RU2016151738A3 (es) 2019-01-30
BR112016030758B1 (pt) 2021-10-13
KR102213527B1 (ko) 2021-02-09
AU2015283662B2 (en) 2020-09-24
IL249814A0 (en) 2017-03-30
WO2016001846A1 (en) 2016-01-07

Similar Documents

Publication Publication Date Title
MX2017000142A (es) Celulas estromales mesenquimatosas para tratar el sindrome de respuesta inflamatoria sistemica.
CY1123065T1 (el) Ανασυνδυασμενα προβιοτικα βακτηριδια
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
CO2017005784A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
CL2016001840A1 (es) Compuestos derivados de pirimidinas fusionadas como inhibidores del complejo p97; composicion farmaceutica y uso en el tratamiento del cancer.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
BR112017006664A2 (pt) terapias de combinação
CO2017007121A2 (es) Compuestos bicíclicos fusionados para el tratamiento de enfermedades
EA201692098A1 (ru) Биокерамические композиции и их применение для биомодулирования
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY37018A (es) Inhibidores bicíclicos de pad4
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
CL2015002897A1 (es) Inhibidores de bace1
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
MX2017003953A (es) Compuestos que contrarrestan el mal olor bajo, de cobertura-alta y metodos uso.
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
BR112018008931A8 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2017000306A (es) Metodos para tratar hipotension.
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения